GSK’s (GSK) “Buy” Rating Reaffirmed at Shore Capital

Shore Capital reissued their buy rating on shares of GSK (LON:GSK) in a research note issued to investors on Wednesday, MarketBeat Ratings reports.

Other research analysts also recently issued research reports about the company. Barclays reissued an equal weight rating and issued a GBX 1,725 ($21.97) target price on shares of GSK in a report on Tuesday, May 7th. JPMorgan Chase & Co. reissued an underweight rating on shares of GSK in a report on Tuesday, June 4th. Deutsche Bank Aktiengesellschaft reissued a buy rating and issued a GBX 1,950 ($24.83) target price on shares of GSK in a report on Wednesday, April 17th. Finally, Berenberg Bank upped their price target on GSK from GBX 1,650 ($21.01) to GBX 1,820 ($23.18) and gave the stock a buy rating in a research report on Wednesday, February 14th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, GSK has a consensus rating of Hold and an average target price of GBX 1,675.63 ($21.34).

GSK Stock Down 0.3 %

GSK stock opened at GBX 1,604.50 ($20.43) on Wednesday. GSK has a fifty-two week low of GBX 1,302.60 ($16.59) and a fifty-two week high of GBX 1,823.50 ($23.22). The business’s 50-day moving average is GBX 1,690.77 and its two-hundred day moving average is GBX 1,620.22. The company has a debt-to-equity ratio of 134.34, a quick ratio of 0.73 and a current ratio of 0.87. The company has a market cap of £65.46 billion, a price-to-earnings ratio of 1,472.02, a P/E/G ratio of 1.19 and a beta of 0.27.

GSK Cuts Dividend

The firm also recently announced a dividend, which will be paid on Thursday, July 11th. Investors of record on Thursday, May 16th will be given a dividend of GBX 15 ($0.19) per share. This represents a dividend yield of 0.9%. The ex-dividend date is Thursday, May 16th. GSK’s dividend payout ratio is currently 5,504.59%.

Insider Buying and Selling

In other GSK news, insider Urs Rohner bought 434 shares of the business’s stock in a transaction that occurred on Wednesday, March 20th. The stock was purchased at an average price of GBX 1,662 ($21.16) per share, for a total transaction of £7,213.08 ($9,185.13). 1.60% of the stock is currently owned by company insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.